Prostate Cancer Registry Presents First Treatment Outcome Data

Prostate Cancer Registry Presents First Treatment Outcome Data
Metastatic castration-resistant prostate cancer (mCRPC) patients who have never received chemotherapy benefit more from treatment than post-chemotherapy patients, according to the first reported outcome data from the The Prostate Cancer Registry, Europe’s first and largest prospective study of men with mCRPC. The results, presented by Janssen-Cilag International at the European Society for Medical Oncology 2016 Congress, which took place Oct. 7-11 in Copenhagen, also reveal that after first-line treatment with Taxotere (docetaxel), patients treated with androgen receptor-targeted agents have higher reductions in PSA levels than those treated with taxanes like Jevtana (cabazitaxel) or Taxotere. The Prostate Cancer Registry was launched in 2013 as a long-term commitment by Janssen to address optimal treatment of mCRPC in routine practice. It was designed in collaboration with mCRPC specialists and assesses patients being managed in a number of oncology and urology settings, with the aim of reflecting routine clinical practice. The Registry is collecting data on a pan-European scale on patient demographics and status, treatment sequencing and effectiveness, ongoing disease management, quality of life, medical resource utilization, and outcomes. The analysis is expected to be completed in 2019. “The Prostate Cancer Registry provides unique insights into the treatment of mCRPC patients from a large, real-world population. With enrollment now c
Subscribe or to access all post and page content.

2 comments

  1. Brian Haselum says:

    Currently I am receiving treatment for early metastasis of PC receiving 6 doses Docetaxel and Goselerin hormone therapy. Since Aug 15 my PSA has dropped from 1.4 to 0.30

Leave a Comment

Your email address will not be published. Required fields are marked *